Moreover, recent works have highlighted that Eprenetapopt (APR-246, PRIMA-1MET), known as a mutant-p53 reactivator, is also able to induce p53-independent ferroptosis by GSH depletion through its capacity to conjugate to free cysteine [147] in several human cancers, including AML [148] and esophageal cancer [149]. Here, TP53 is linked to cancer.